SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern-Reference-Cited by-同舟云学术

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

Published:2022-10 Issue: Volume:84 Page:104270
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Aggarwal Anupriya,Akerman Anouschka^ORCID,Milogiannakis Vanessa,Silva Mariana Ruiz^ORCID,Walker Gregory,Stella Alberto Ospina,Kindinger Andrea,Angelovich Thomas,Waring Emily,Amatayakul-Chantler Supavadee,Roth Nathan,Manni Sandro,Hauser Thomas,Barnes Thomas,Condylios Anna,Yeang Malinna,Wong Maureen,Jean Tyra,Foster Charles S.P.,Christ Daniel,Hoppe Alexandra Carey,Munier Mee Ling,Darley David,Churchill Melissa,Stark Damien J.,Matthews Gail,Rawlinson William D.,Kelleher Anthony D.,Turville Stuart G.^ORCID

Funder

National Health and Medical Research Council

CSL Limited

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference39 articles.

1. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation;Rajah;EMBO J,2021

2. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells;Zhao;Emerg Microbes Infect,2022

3. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity;Meng;Nature,2022

4. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters;Halfmann;Nature,2022

5. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant;Suzuki;Nature,2022

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical performance of a rapid RT-PCR assay using STANDARD™ M10 SARS-CoV-2 between July 2022 and January 2023 in Korea;Diagnostic Microbiology and Infectious Disease;2024-12

2. Bebtelovimab‐bound SARS‐CoV‐2 RBD mutants: resistance profiling and validation with escape mutations, clinical results, and viral genome sequences;FEBS Letters;2024-08-06

3. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2;Clinical Microbiology and Infection;2024-08

4. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages;Biomedicine & Pharmacotherapy;2024-08

5. Dissecting human monoclonal antibody responses from mRNA- and protein-based XBB.1.5 COVID-19 monovalent vaccines;2024-07-16